Vanguard Group Inc. Boosts Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Vanguard Group Inc. increased its stake in Supernus Pharmaceuticals by 0.2%, acquiring 13,133 additional shares, bringing their total ownership to 6,163,892 shares, valued at approximately $201.87 million.
• Several institutional investors have significantly increased their holdings in Supernus, with Woodline Partners LP growing its stake by 124.8% during the last quarter.
• Supernus Pharmaceuticals received a rating upgrade from Wall Street analysts, with Cantor Fitzgerald raising the target price from $42 to $46 and a consensus rating of "Moderate Buy."

Vanguard Group Inc. grew its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163,892 shares of the specialty pharmaceutical company's stock after purchasing an additional 13,133 shares during the period. Vanguard Group Inc. owned approximately 11.01% of Supernus Pharmaceuticals worth $201,867,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. GW&K Investment Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after purchasing an additional 176,091 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Supernus Pharmaceuticals by 18.3% in the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after purchasing an additional 110,867 shares in the last quarter. Ashford Capital Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 0.3% in the 4th quarter. Ashford Capital Management Inc. now owns 545,775 shares of the specialty pharmaceutical company's stock valued at $19,735,000 after purchasing an additional 1,740 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Supernus Pharmaceuticals by 33.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after purchasing an additional 136,870 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in shares of Supernus Pharmaceuticals by 124.8% in the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after purchasing an additional 235,257 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 1.0%

SUPN stock traded down $0.45 during midday trading on Monday, hitting $44.43. 645,740 shares of the company's stock were exchanged, compared to its average volume of 1,084,880. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The firm has a 50 day moving average price of $35.64 and a 200-day moving average price of $33.69. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of 38.63 and a beta of 0.74.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director directly owned 46,307 shares in the company, valued at $1,956,933.82. The trade was a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders have sold 152,826 shares of company stock worth $6,424,773 in the last three months. 8.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SUPN has been the topic of several research analyst reports. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $41.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.